152 Chapter 8 REFERENCES 1. Berntorp E, Fischer K, Hart DP, Mancuso ME, Stephensen D, Shapiro AD, Blanchette V. Haemophilia. Nat Rev Dis Primers. 2021; 7: 45. 2. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A, Subcommittee on Factor Viii FIX, Rare Coagulation Disorders of the S, Standardization Committee of the International Society on T, Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014; 12: 1935-1939. 3. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, Carcao M, Mahlangu J, Ragni MV, Windyga J, Llinas A, Goddard NJ, Mohan R, Poonnoose PM, Feldman BM, Lewis SZ, van den Berg HM, Pierce GF, panelists WFHGftMoH, co a. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020; 26: 1-158. 4. Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med. 2001; 344: 1773-1779. 5. Ay C, Perschy L, Rejto J, Kaider A, Pabinger I. Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting. Ann Hematol. 2020; 99: 2763-2771. 6. Berntorp E, Dolan G, Hay C, Linari S, Santagostino E, Tosetto A, Castaman G, Alvarez-Roman MT, Parra Lopez R, Oldenburg J, Albert T, Scholz U, Holmstrom M, Schved JF, Trossaert M, Hermans C, Boban A, Ludlam C, Lethagen S. European retrospective study of real-life haemophilia treatment. Haemophilia. 2017; 23: 105-114. 7. Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jimenez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, KruseJarres R. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018; 379: 811-822. 8. Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia. 2022; 28: 103-110. 9. Scott LJ, Kim ES. Emicizumab-kxwh: First Global Approval. Drugs. 2018; 78: 269-274. 10. Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, Mahlangu J, Young G, Kruse-Jarres R, Mancuso ME, Niggli M, Howard M, Bienz NS, Shima M, Jimenez-Yuste V, Schmitt C, Asikanius E, Levy GG, Pipe SW, Oldenburg J. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021; 137: 2231-2242. 11. Schmitt C, Emrich T, Chebon S, Fernandez E, Petry C, Yoneyama K, Kiialainen A, Howard M, Niggli M, Paz-Priel I, Chang T. Low immunogenicity of emicizumab in persons with haemophilia A. Haemophilia. 2021; 27: 984-992. 12. European Medicines Agency. Hemlibra (emicizumab) Summary of Product Characteristics. 2018. https:// www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf. Accessed on 01-09-2022 13. Yoneyama K, Schmitt C, Kotani N, Levy GG, Kasai R, Iida S, Shima M, Kawanishi T. A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. Clin Pharmacokinet. 2018; 57: 1123-1134. 14. Donners A, Rademaker CMA, Bevers LAH, Huitema ADR, Schutgens REG, Egberts TCG, Fischer K. Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review. Clin Pharmacokinet. 2021; 60: 1395-1406.
RkJQdWJsaXNoZXIy MTk4NDMw